Medtronic (MDT) Tops Q1 EPS by 9c, Raises EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Medtronic, Inc. (MDT) PT Raised to $155 at Jefferies
August 25, 2021 7:30 AM EDTJefferies analyst Raj Denhoy raised the price target on Medtronic, Inc. (NYSE: MDT) to $155.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "MDT posted a ~$120mn/$0.10 beat on out-performance in MedSurg on elective procedure recovery, share gains in Cardio/Micra,... More
Medtronic (MDT) Tops FQ1 Views, Analysts Raise PTs on 'Solid' Print
August 25, 2021 6:52 AM EDTShares of Medtronic (NYSE: MDT) closed over 3% higher yesterday after the company reported better-than-expected FQ1 results.
Medtronic reported a Q1 EPS of $1.41 to top the analyst estimates of $1.32. Revenue for the quarter came in at $7.99 billion versus the consensus estimate of $7.85 billion.
Fiscal 2022 is off to a strong start with our first quarter results coming in ahead of our expectations, reflecting solid execution and continued procedure volume recovery, with most of our businesses at or above pre-COVID levels," said... More
Medtronic, Inc. (MDT) PT Raised to $145 at Stifel
August 25, 2021 6:33 AM EDTStifel analyst Rick Wise raised the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $140.00) while maintaining a Buy rating.
The analyst commented, "Despite some signs of new COVID-related slowdowns in late-July, Medtronic did start the F2022 year with a better-than-expected overall performance. Nicely-exceeding Stifel/Consensus estimates (Sales: $7.866B/$7.871B; EPS: $1.32), Medtronic reported F1Q sales... More
